2m 2m 2m 2m 2m 2m 2m
- $135.7MMarket Cap
- 40.09%1-Year Change
- Specialty ChemicalsIndustry
Kraig Biocraft (KBLB)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 65
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength
Several companies are transitioning from strategic announcements to operational execution. Kraig Biocraft Laboratories has begun production of recombinant spider silk and received National Geographic cover feature. Rackspace and Palantir announced a strategic partnership to deploy enterprise AI in production environments. Ensysce Biosciences initiated a formal strategic review to explore partnerships and enhance shareholder value.
02/27/2026, 9:45 AM • GlobeNewswire
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum
Small- and mid-cap stocks are gaining momentum on execution milestones and transformative deals. Interactive Strength surged 40% after acquiring Ergatta to boost revenue guidance by 50%. Kraig Biocraft Laboratories activated its 2026 production program for spider silk manufacturing. Theriva Biologics out-licensed an asset to focus on its pancreatic cancer program, while PMGC Holdings' subsidiary filed patents for animal health applications.
02/19/2026, 11:00 AM • GlobeNewswire
Electrify, Simplify, Spin-Off & Scale
Several companies announced significant developments in electrification, materials technology, industrial restructuring, and AI infrastructure, including partnerships, strategic sales, and infrastructure expansion.
11/21/2025, 10:00 AM • GlobeNewswire
Strong Earnings and Biotech Resilience Define the Midweek Momentum
Several biotech companies reported significant developments, including Kraig Labs' breakthrough in spider silk production, Salarius Pharmaceuticals' public offering, Humacyte's Q3 progress, and CorMedix's record quarterly earnings.
11/12/2025, 11:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Kraig Biocraft Laboratories, Inc. develops protein-based fibers using recombinant DNA technology for commercial applications in the textile and specialty fiber industries in the United States. The company's primary proprietary fiber technology includes natural and engineered variants of spider silk produced in domesticated mulberry silkworms, as well as uses genetically engineered silkworms that produce spider silk proteins to create its recombinant spider silk. Its products are used in performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics, and other applications; and military and police for its ballistic protection. Kraig Biocraft Laboratories, Inc. was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.
Key Executives
- Kim Kraig Thompson
- Jonathan R. Rice
- Kenneth Le
- Xiaoli Zhang
Current Ownership Distribution
- Other904.5M (81.26%)
- Insiders207.4M (18.63%)
- Institutions1.2M (0.11%)
- Mutual Funds0 (0.00%)